An orthotopic syngeneic mouse model of bortezomib-resistant multiple myeloma.

Manjun Li, Melissa K Bennett, John Toubia, Victoria S Pope, Melinda N Tea, Sarah Tamang, Michael S Samuel, Paul H Anderson, Briony L Gliddon, Jason A Powell, Stuart M Pitson

British journal of haematology 2024 Feb

filter terms:

While bortezomib has significant benefits in multiple myeloma (MM) therapy, the disease remains incurable due to the invariable development of bortezomib resistance. This emphasises the need for advanced models for preclinical evaluation of new therapeutic approaches for bortezomib-resistant MM. Here, we describe the development of an orthotopic syngeneic bortezomib-resistant MM mouse model based on the most well-characterised syngeneic MM mouse model derived from spontaneous MM-forming C57BL/KaLwRij mice. Using bortezomib-resistant 5TGM1 cells, we report and characterise a robust syngeneic mouse model of bortezomib-resistant MM that is well suited to the evaluation of new therapeutic approaches for proteasome inhibitor-resistant MM. © 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Citation

Manjun Li, Melissa K Bennett, John Toubia, Victoria S Pope, Melinda N Tea, Sarah Tamang, Michael S Samuel, Paul H Anderson, Briony L Gliddon, Jason A Powell, Stuart M Pitson. An orthotopic syngeneic mouse model of bortezomib-resistant multiple myeloma. British journal of haematology. 2024 Feb;204(2):566-570